Loading...
Docoh

Cyclo Therapeutics (CYTH)

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

CYTH stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

15 Aug 22
16 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 7.45M 7.45M 7.45M 7.45M 7.45M 7.45M
Cash burn (monthly) 1.45M 334.17K 1.15M 1.09M 1.45M 1.24M
Cash used (since last report) 2.28M 524.99K 1.81M 1.71M 2.28M 1.94M
Cash remaining 5.18M 6.93M 5.64M 5.75M 5.17M 5.51M
Runway (months of cash) 3.6 20.7 4.9 5.3 3.6 4.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 Aug 22 Ostronic Francis Patrick Common Stock Grant Acquire A No No 0 7,162 0 145,687
2 Aug 22 Toig Randall M. Common Stock Grant Acquire A No No 0 3,093 0 51,625
2 Aug 22 Sieger Markus Common Stock Grant Acquire A No No 0 5,762 0 91,674
20 May 22 Ostronic Francis Patrick Common Stock Buy Acquire P No No 2.0399 4,988 10.18K 138,525
20 May 22 Ostronic Francis Patrick Common Stock Buy Acquire P No No 2 12 24 133,537
16 May 22 Tate Jeffrey Common Stock Buy Acquire P No No 2.118 3,000 6.35K 32,160
7.6% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 14 6 +133.3%
Opened positions 12 2 +500.0%
Closed positions 4 11 -63.6%
Increased positions 1 0 NEW
Reduced positions 0 2 EXIT
13F shares Current Prev Q Change
Total value 4.17M 3.11M +34.2%
Total shares 643.49K 1.15M -44.1%
Total puts 0 0
Total calls 0 294.93K EXIT
Total put/call ratio
Largest owners Shares Value Change
Vanguard 255.07K $808K NEW
Hirschman Orin 209.38K $2.79M 0.0%
Renaissance Technologies 75.79K $240K NEW
Geode Capital Management 48.32K $153K NEW
STT State Street 28.3K $90K NEW
BLK Blackrock 18.2K $58K NEW
UBS UBS Group AG - Registered Shares 2.29K $7K +55.4%
WFC Wells Fargo & Co. 2.05K $6K NEW
Tower Research Capital 1.51K $5K NEW
C Citigroup 1.23K $4K NEW
Largest transactions Shares Bought/sold Change
Verition Fund Management 0 -800K EXIT
Vanguard 255.07K +255.07K NEW
Renaissance Technologies 75.79K +75.79K NEW
Worth Venture Partners 0 -74.74K EXIT
Empery Asset Management 0 -65K EXIT
Geode Capital Management 48.32K +48.32K NEW
STT State Street 28.3K +28.3K NEW
BLK Blackrock 18.2K +18.2K NEW
WFC Wells Fargo & Co. 2.05K +2.05K NEW
Tower Research Capital 1.51K +1.51K NEW

Financial report summary

?
Competition
Orphazyme A/S

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: bore
Removed: investor, partially